Compared with cytologic testing, HPV-based screening reduced the incidence of invasive cervical cancer among European women.
Because cervical cancer is relatively uncommon in developed countries, reliable comparison of screening methods for detection of this cancer and its precursors has been difficult. Investigators pooled data from four randomized trials in different European countries to compare human papillomavirus (HPV) testing with cytologic (Pap) testing and to determine relative risk for cervical cancer in women screened by each method.
More than 175,000 women (age range, 20–64) participated, with median follow-up of 6.5 years. In all, 107 cases of invasive cervical cancer were identified. Risk for cervical cancer was similar in the two arms during the initial 2.5 years of follow-up (rate ratio [RR], 0.79) but diverged significantly in favor of HPV testing…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)